City

Atlanta (1)

Boston (1)

Overall Status

Not yet recruiting (2)

Phase

phase 2 (1)

Sponsor

Dana-Farber Cancer Institute (1)

Emory University (1)

Collaborator

Astellas Pharma Inc (1)

EMD Serono (1)

Merck Sharp & Dohme LLC (1)

National Cancer Institute (NCI) (1)

National Comprehensive Cancer Network (1)

Seagen Inc. (1)

Intervention

biospecimen collection (1)

computed tomography (1)

enfortumab vedotin (1)

geriatric-8 survey (1)

magnetic resonance imaging (1)

national comprehensive cancer network/functional assessment of cancer therapy bladder symptom index-18 (fbisi-18) (1)

patient-reported outcomes version of the common terminology criteria for adverse events (pro-ctcae®) (1)

pembrolizumab (1)

questionnaire administration (1)

Study Documents

Intervention Type

behavioral (1)

biological (1)

drug (1)

other (1)

procedure (1)

Funder Type

Other (2)

Study Type

Interventional (1)

Observational (1)

unresectable bladder carcinoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Cisplatin-Ineligible Metastatic Bladder Cancer and The Role of

Not yet recruiting

Bladder Cancer
+3 more

Geriatric-8 Survey
+2 more

Boston, Massachusetts
+1 more

Nov 14, 2023

Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,

Not yet recruiting

Bladder Squamous Cell Carcinoma
+10 more

Biospecimen Collection
+5 more

Atlanta, Georgia
+3 more

Feb 20, 2023